[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Bluefin Biomedicine, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":69},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100615057","phase-2-a-study-evaluating-bfb759-in-moderate-to-severe-hidradenitis-suppurativa-100615057",false,"NCT07287644","A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa","A Phase 2, Dose Ranging, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BFB759 in Patients With Moderate to Severe Hidradenitis Suppurativa","COMPASS 2-HS","Inclusion Criteria:\n\n* Are adults (18 to 75 years) with a diagnosis of hidradenitis suppurativa for at least one year.\n* Have moderate to severe disease not well controlled by systemic antibiotic treatment.\n* Are willing to follow study instructions, attend regular visits, and avoid certain other medications during the study.\n\nExclusion Criteria:\n\n* Have certain infections or other immune conditions.\n* Recently used medications that could interfere with the study.\n* Are pregnant or breastfeeding.","ALL","18 Years","75 Years",{"count":21,"type":22},210,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE2","PHASE3","This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.",[29],"Hidradenitis Suppurativa (HS)",[31,32],"Hidradenitis Suppurativa","acne inversa","RECRUITING","2026-05-28",{"date":36,"type":37},"2026-05-29","ACTUAL",{"date":39,"type":37},"2025-11-03",{"date":41,"type":22},"2027-08-01",{"name":43,"class":44},"Bluefin Biomedicine, Inc.","INDUSTRY",58,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":27,"conditions":57,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100601053","phase-2-a-study-evaluating-bfb759-in-moderate-to-severe-atopic-dermatitis-100601053","NCT07105488","A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis","A Phase 2, Parallel-arm, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of BFB759 in Patients With Atopic Dermatitis (COMPASS 2-AD)","COMPASS 2-AD","Inclusion Criteria:\n\n* Are adults (18-75) with a diagnosis of atopic dermatitis for at least one year.\n* Have moderate to severe disease not adequately controlled by topical treatments.\n* Are willing to follow study instructions, attend regular visits, and avoid certain other medications during the study.\n\nExclusion Criteria:\n\n* Have certain infections or other immune conditions.\n* Recently used medications that could interfere with the study.\n* Are pregnant or breastfeeding.",{"count":55,"type":22},225,[25],[58],"Atopic Dermatitis (AD)",[60,61],"Atopic Dermatitis","Eczema",{"date":36,"type":37},{"date":64,"type":37},"2025-07-15",{"date":66,"type":22},"2027-03-31",{"name":43,"class":44},88,""]